ALX Oncology Company
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Estimated Revenue:
Less than $1M
Technology:
Cancer
Industry:
Biopharma, Biotechnology, Health Care, Life Science, Therapeutics
Investor Type:
IPO
Last Funding Type:
Initial Coin Offering
Total Funding:
166000000
Funding Status:
IPO
Headquarters:
San Francisco, California, United States
Investors Number:
10
Last Funding Date:
2020
Founded Date:
2015
Employee Number:
11-50